MORRISTOWN, N.J. — February 19, 2026 — Leads & Copy — Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company, will participate in several upcoming healthcare conferences in February and March.
Reunion Neuroscience is focused on advancing next-generation psychedelic-inspired therapeutic solutions for underserved mental health disorders.
The conferences include:
Oppenheimer 36th Annual Healthcare Life Sciences Conference, February 25-26, 2026 (Virtual). Reunion’s presentation is scheduled for Thursday, February 26th at 12:40 p.m. ET.
TD Cowen 46th Annual Healthcare Conference, March 2-4, 2026 in Boston, MA.
Leerink Partners Global Healthcare Conference, March 8-11, 2026 in Miami, FL.
The Citizens Life Sciences Conference, March 10-11, 2026 in Miami, FL. The company will present on Tuesday, March 10th at 11:20 a.m. ET.
Barclays Global Healthcare Conference, March 10-12, 2026 in Miami, FL. Reunion is scheduled to present on Wednesday, March 11th at 9:00 a.m. ET.
Members of the Reunion management team will host one-on-one investor meetings during each conference.
Reunion Neuroscience is actively investigating the use of its lead product candidate, RE104, in postpartum depression, adjustment disorder and generalized anxiety disorder and may in the future expand to additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care. Reunion has advanced a lead candidate, RE245, from its non-psychedelic discovery program and plans to file an IND in 2026.
Source: Reunion Neuroscience
